(Seoul=NSP News Agency) soon ki Lee Journalist = Samsung Biologics has unveiled ‘S-Cellerate’, a contract development organization(CDO) platform that dramatically shortens the period from cell line development to IND submission and from process characterization(PC) to biologics license application(BLA).
S-Cellerate is a base technology platform that standardizes the services required for biopharmaceutical development and supports them more quickly, and consists of two services.
One is the S-Cellerate to IND platform service, which supports from early cell line development to the development of production processes and analysis methods, non-clinical and clinical substance production, and investigational new drug application(IND).
The second is the S-Cellerate to BLA platform service, which extends to biologics license application(BLA) for commercial sales through process characterization(PC) and process performance qualification(PPQ) in the late development stage.
The S-Cellerate, announced by Samsung Biologics, is a CDO platform that integrates Samsung Biologics’ accumulated know-how, expertise, and innovative technology across all areas of consignment development services.
It is possible in as early as 9 months from cell line development to investigational new drug application(IND) through optimized and standardized processes for each development stage.
In addition, from process characterization to biologics license application(BLA), such as process validation, it is possible to receive services necessary for drugs that are about to enter the market.
NSP News Agency soon ki Lee Journalist firstname.lastname@example.org
Copyright ⓒ Korea's economic news agency NSP NEWS·NSP TV. All rights reserved-Redistribution Prohibited.